Publications by authors named "Byoung Chol Cho"
Article Synopsis
- The KEYNOTE-590 study found that combining pembrolizumab with chemotherapy significantly improved survival rates and overall health outcomes for patients with advanced esophageal cancer compared to chemotherapy alone.
- A health-related quality of life analysis involving 730 patients showed that those receiving pembrolizumab plus chemotherapy experienced less dysphagia and pain compared to those on placebo plus chemotherapy, although overall quality of life scores were similar.
- The study concluded that pembrolizumab plus chemotherapy not only maintained quality of life after 18 weeks but also demonstrated effectiveness, supporting its use as a first-line treatment for advanced esophageal cancer.
